Brodalumab治疗中重度斑块状银屑病的希腊真实世界研究(BrIDGE研究)
主要终点为24周PASI100比例,实际观测数据为42.0%,104周达65%;12-16周PASI75/90/100分别为70.2%/47.5%/32.0%,sPGA 0/1为72.6%。治疗依从性98.9%,DLQI与PSI评分自基线至104周分别下降11.4±7.0和15.4±6.5分。
要点
- 24周PASI100实际观测比例为42.0%,104周达65%。
- 12-16周PASI75/90/100为70.2%/47.5%/32.0%,sPGA 0/1为72.6%。
- 104周DLQI与PSI较基线分别下降11.4±7.0和15.4±6.5分。
核心结论
- Brodalumab可快速且持久地改善中重度斑块状银屑病,并提高生活质量。
研究设计与样本
- 缺失数据采用实际观测分析及末次观测结转、最差情形、最佳情形三种填补方法。
主要发现
- 实际观测数据下,42.0%患者在25.9±3.5周达到PASI100,65%患者在104周达到PASI100。
- 12-16周时70.2%、47.5%、32.0%患者分别达到PASI75、PASI90、PASI100,72.6%达到sPGA 0/1。
- 24、52、104周达到sPGA 0/1的患者比例分别为82.8%、89.2%、92.5%。
- 达到PASI100的时间在12-16周为13.7±1.3周,52周为52.1±3.4周,104周为105.5±4.8周。
- DLQI和PSI评分自基线至104周分别平均下降11.4±7.0和15.4±6.5分,治疗依从性为98.9%。
临床怎么用
- Brodalumab可作为中重度斑块状银屑病快速起效且长期维持的治疗选择。
- 治疗中需关注12-16周早期应答及长期PASI90/100维持情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real-life data remain scarce. BrIDGE was an observational, prospective, single-cohort, multicentre study that recruited patients with moderate-to severe plaque psoriasis in Greece. OBJECTIVES: The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short-term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12-16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab. METHODS: Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, 'worst case' and 'best case' scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables. RESULTS: Based on the 'as observed data', 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12-16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12-16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%. CONCLUSIONS: Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate-to-severe psoriasis patients.
引用
- Rigopoulos D, Tampouratzi E, Angelakopoulos C, et al. Real-world data on the effectiveness of brodalumab in patients with moderate-to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study). J Eur Acad Dermatol Venereol. 2024. PMID: 38308561. doi:10.1111/jdv.19816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。